Gut Microbiota Metagenomics for Chronic Liver Disease

NCT ID: NCT04339725

Last Updated: 2020-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-01

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gut microbiota modulation has effect on chronic liver disease

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma.

Gut microbiota plays an important roles in the chronic liver disease. It can suppress the progression of the liver disease by moulation gut microbiota.

The investigators are still evaluating the effect of gut microbiota on the liver disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Disease Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fecal DNA

Extraction fecal DNA and compare disease group to normal group

DNA extraction

Intervention Type OTHER

Extraction fecal DNA and compare disease group to normal group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DNA extraction

Extraction fecal DNA and compare disease group to normal group

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 19+
* Normal : AST or ALT level \< 50IU/L, BMI \< 25
* Liver disease : AST or ATL level ≥ 50IU/L, BMI ≥ 25
* Patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer)

Exclusion Criteria

* Normal : AST or ATL level ≥ 50IU/L, BMI ≥ 25
* Liver disease : AST or ALT level \< 50IU/L, BMI \< 25
* If the patient refuses
Minimum Eligible Age

31 Years

Maximum Eligible Age

82 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chuncheon Sacred Heart Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ki Tae Suk

Proffesor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital

Chuncheon, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Park IG, Yoon SJ, Won SM, Oh KK, Hyun JY, Suk KT, Lee U. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease. Sci Rep. 2024 Jul 12;14(1):16122. doi: 10.1038/s41598-024-60768-2.

Reference Type DERIVED
PMID: 38997279 (View on PubMed)

Ganesan R, Gupta H, Jeong JJ, Sharma SP, Won SM, Oh KK, Yoon SJ, Han SH, Yang YJ, Baik GH, Bang CS, Kim DJ, Suk KT. Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease. Hepatol Int. 2024 Apr;18(2):486-499. doi: 10.1007/s12072-023-10518-9. Epub 2023 Mar 31.

Reference Type DERIVED
PMID: 37000389 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STOOL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.